{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:24:45Z","timestamp":1780514685810,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,17]]},"DOI":"10.7759\/cureus.86246","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:44:52Z","timestamp":1750221892000},"source":"Crossref","is-referenced-by-count":1,"title":["Statin-Associated Myositis in a High-Risk Cardiovascular Patient: Challenges in Reintroducing Therapy"],"prefix":"10.7759","author":[{"given":"Guanming","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaida","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizeth","family":"Diaz Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden BA","year":"2023","unstructured":"Warden BA, Guyton JR, Kovacs AC, et al.. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023, 17:19-39. 10.1016\/j.jacl.2022.09.001","journal-title":"J Clin Lipidol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations","volume":"14","author":"Selva-O'Callaghan A","year":"2018","unstructured":"Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fern\u00e1ndez I, et al.. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018, 14:215-24. 10.1080\/1744666X.2018.1440206","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.048","article-title":"Atherosclerotic risk and statin use among patients with peripheral artery disease","volume":"76","author":"Colantonio LD","year":"2020","unstructured":"Colantonio LD, Hubbard D, Monda KL, et al.. Atherosclerotic risk and statin use among patients with peripheral artery disease. J Am Coll Cardiol. 2020, 76:251-64. 10.1016\/j.jacc.2020.05.048","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2018.07.089","article-title":"Statin use improves limb salvage after intervention for peripheral arterial disease","volume":"70","author":"Parmar GM","year":"2019","unstructured":"Parmar GM, Novak Z, Spangler E, Patterson M, Passman MA, Beck AW, Pearce BJ. Statin use improves limb salvage after intervention for peripheral arterial disease. J Vasc Surg. 2019, 70:539-46. 10.1016\/j.jvs.2018.07.089","journal-title":"J Vasc Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226619","article-title":"False versus true statin intolerance in patients with peripheral artery disease","volume":"11","author":"Dopheide JF","year":"2022","unstructured":"Dopheide JF, Gillmann P, Spirk D, Khorrami Borozadi M, Adam L, Drexel H. False versus true statin intolerance in patients with peripheral artery disease. J Clin Med. 2022, 11:6619. 10.3390\/jcm11226619","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000371548","article-title":"Rhabdomyolysis in the setting of induced hypothyroidism and statin therapy: a case report","volume":"4","author":"Jbara Y","year":"2015","unstructured":"Jbara Y, Bricker D. Rhabdomyolysis in the setting of induced hypothyroidism and statin therapy: a case report. Eur Thyroid J. 2015, 4:62-4. 10.1159\/000371548","journal-title":"Eur Thyroid J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1394455","article-title":"Statin drug interactions and related adverse reactions: an update","volume":"17","author":"Bellosta S","year":"2018","unstructured":"Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018, 17:25-37. 10.1080\/14740338.2018.1394455","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101714","article-title":"Management of patients with statin intolerance","volume":"37","author":"Martirossian AN","year":"2023","unstructured":"Martirossian AN, Goldberg AC. Management of patients with statin intolerance. Best Pract Res Clin Endocrinol Metab. 2023, 37:101714. 10.1016\/j.beem.2022.101714","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3549402","article-title":"Vitamin D serum levels in patients with statin-induced musculoskeletal pain","volume":"2019","author":"Pennisi M","year":"2019","unstructured":"Pennisi M, Di Bartolo G, Malaguarnera G, Bella R, Lanza G, Malaguarnera M. Vitamin D serum levels in patients with statin-induced musculoskeletal pain. Dis Markers. 2019, 2019:3549402. 10.1155\/2019\/3549402","journal-title":"Dis Markers"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0513-7","article-title":"Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale","volume":"16","author":"Teramoto T","year":"2017","unstructured":"Teramoto T, Kondo A, Kiyosue A, et al.. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis. 2017, 16:121. 10.1186\/s12944-017-0513-7","journal-title":"Lipids Health Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen SE","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al.. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016, 315:1580-90. 10.1001\/jama.2016.3608","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes ES","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015, 36:1012-22. 10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"74","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019, 74:1376-414. 10.1016\/j.jacc.2019.03.009","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton JR","year":"2014","unstructured":"Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014, 8:S72-81. 10.1016\/j.jacl.2014.03.002","journal-title":"J Clin Lipidol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358460-statin-associated-myositis-in-a-high-risk-cardiovascular-patient-challenges-in-reintroducing-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:44:53Z","timestamp":1750221893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358460-statin-associated-myositis-in-a-high-risk-cardiovascular-patient-challenges-in-reintroducing-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.86246","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}